0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > EpCAM

EpCAM

EpCAM Molecule Information

Name:Epithelial cell adhesion molecule
Target Synonym:MIC18;EPCAM;GA733-2 ;Epithelial cell adhesion molecule;EGP;Epithelial cell surface antigen;TACSTD1;hEGP314;KS 1/4 antigen;M1S2;TROP1;Major gastrointestinal tumor-associated protein GA733-2;Epithelial glycoprotein 314;EGP314;M4S1;Cell surface glycoprotein
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:22
Lastest Research Phase:Approved

EpCAM Protein Product ListCompare or Buy

"

EpCAM Molecule Synonym Name

EPCAM,TACSTD1,TROP1,CD326,DIAR5,EGP2,EGP314,EGP40,ESA,GA733-2,HNPCC8,HNPCC-8,KS1/4,KSA,M4S1,MIC18,MK1

EpCAM Molecule Background

EpCAM is also known as CO171A, EGP, EGP40,GA7332, KSA, M4S, MIC18, MK1, TROP1, hEGP2, and is a pan-epithelial differentiation antigen that is expressed on almost all carcinomas as 17-1A(mAb) antigen. Its constitutional function is being elucidated. It is intricately linked with the Cadherin-Catenin pathway and hence the fundamental WNT pathway responsible for intracellular signaling and polarity. The epithelial cell adhesion molecule (Ep-CAM) is known to express in most epithelial malignancies and was reported as a tumor marker or a candidate of molecular targeting therapy. Ep-CAM cross signaling with N-cadherin involves Pi3K, resulting in the abrogation of the cadherin adhesion complexes in epithelial cells was reported. And Epithelial cell adhesion molecule (Ep-CAM) recently received increased attention as a prognostic factor in breast cancer.

EpCAM References

"

EpCAM Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
VB1-050 (Sesen Bio) VBX-050; VB1-050,VBX 050; VB1 050,VBX050; VB1050 Preclinical Sesen Bio Colon cancer, Gastric cancer, Prostate cancer, Liver cancer Details
Anti-EPCAM CAR-T cell therapy (Sinobioway) Phase Ⅱ Sinobioway Cell Therapy Gastric cancer, Liver cancer Details
M-701 M-701 Phase Ⅰ YZY Bio Malignant Ascites Details
Anti-17-1A monoclonal antibody 3622W94 Phase Ⅱ GlaxoSmithKline Non small cell lung cancer (NSCLC), Prostate cancer Details
ING-1 ING-1 Phase Ⅰ Xoma, Aduro BioTech Adenocarcinoma Details
Citatuzumab bogatox VB6-845; VB6-845d Phase Ⅰ Viventia Biotech, Sesen Bio Solid tumours Details
Anti-KSA cancer vaccine (IDM Pharma) Phase Ⅰ IDM Pharma, Walter Reed Army Institute of Research Prostate cancer, Colorectal cancer Details
A-337 A-337 Phase Ⅰ Generon Corporation Solid tumours Details
VB-4011 (Sesen Bio) VB-4011 Preclinical Viventia Biotech, Sesen Bio Cancer Details
VB1-008 (Sesen Bio) VB1-008; VBX-008,VB1 008; VBX 008,VB1008; VBX008 Preclinical Sesen Bio Cancer Details
NP-1 (Sesen Bio) NP-1 (Sesen Bio),NP 1 (Sesen Bio),NP1 (Sesen Bio) Preclinical Sesen Bio Cancer Details
Oportuzumab monatox 4D5MOCB-ETA; VB4-845; VB-4847; VB-845; B-4845 BLA Filing Viventia Biotech, Sesen Bio Bladder cancer Details
Monoclonal antibody BIS-1 Phase Ⅰ University Hospital Groningen Malignant pleural effusion, Renal carcinoma, Malignant Ascites Details
VB-6901 (Sesen Bio) VB-6901 Preclinical Viventia Biotech, Sesen Bio Cancer Details
186Re-NR-LU-10 186Re-NR-LU-10; NR-LU-10-186Re Phase Ⅰ Poniard Pharmaceuticals Solid tumours Details
Anti-EpCAM cancer vaccine (Aphton) IGN-101 Phase Ⅲ Aphton Corporation, Altropus Non small cell lung cancer (NSCLC) Details
Catumaxomab LP000 Withdrawn Trion Research, Neovii Biotech, LintonPharm Malignant Ascites Details
AT-003 AT-003 Preclinical Affitech Cancer Details
VB-6050 (Sesen Bio) VB-6050 Preclinical Viventia Biotech, Sesen Bio Cancer Details
Monoclonal antibody 323A3 Phase Ⅰ Centocor, Nonindustrial source Breast cancer, Cancer Details
Edrecolomab Withdrawn Johnson & Johnson, GlaxoSmithKline, Ajinomoto Colorectal cancer Details
Solitumomab AMG-110; MT-110 Phase Ⅰ Micromet Solid tumours Details
Adecatumumab MT-201,MT201 Phase Ⅱ Amgen, Merck Serono Prostate cancer, Breast cancer, Colorectal cancer Details

This web search service is supported by Google Inc.

totop